ClinicalTrials.gg
CompletedNCT01550965InspirAdaUpdated Jul 2, 2018Results posted

A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting

A Phase 3 interventional study of Adalimumab in Ulcerative Colitis, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-07-02.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
463
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies testing adalimumab in Colitis, Ulcerative — 1 open to participants now, 2 under way, none of them phase 3. Adalimumab · Colitis, Ulcerative.

Enrollment
5th of 18
463 · median 152
Started
2012
with 2 others
Phase 3
10 of 18
none open now
Registered
7th of 18
by date
Lead sponsor
3 of 18
AbbVie (prior sponsor, Abbott)

Among the 18 studies testing adalimumab in Colitis, Ulcerative, this one is the 5th largest by enrollment, is one of 3 that started in 2012, is one of 10 in phase 3, and was the 7th registered.

Colitis, Ulcerative

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

1 of the 18 studies testing adalimumab in Colitis, Ulcerative is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing adalimumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

This study evaluated the quality of life (QOL) and economic impact of adalimumab treatment in participants with ulcerative colitis (UC).

Read the detailed description

This was a single arm, open-label, multicenter study. The primary objectives were to study the effect of adalimumab on QOL (as measured by Short Inflammatory Bowel Disease Questionnaire (SIBDQ)), the utilization of health care resources, and the costs of care for subjects with UC who were treated with adalimumab in the usual clinical practice setting. The secondary objectives were to further assess the effect of adalimumab on disease activity and to collect additional safety data in subjects with UC.

03

Conditions studied

  • Ulcerative Colitis

Keywords

  • Quality of Life
  • Costs of Ulcerative Colitis
  • Health Care Utilization
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants had to be a male or female between the ages of 18 and 75 years old at the time of the Screening Visit.
  2. Participants who had a diagnosis of ulcerative colitis (UC) greater than 90 days prior to baseline (week 0) and failed conventional treatment.
  3. Participants diagnosis of active UC was confirmed by a colonoscopy with or flexible sigmoidoscopy with biopsy.
  4. Participants who had active UC with a Physicians Global Assessment (PGA) score of 2 or 3 and Short Inflammatory Bowel Disease Questionnaire (SIBDQ) ≤ 45 at baseline (week 0).
  5. Concurrent therapy was required for participants who were previously treated with or (azathioprine (AZA) or 6-mercaptopurine (6-MP)) and, in the judgment of the investigator, had failed to respond to or could not tolerate their treatment. Participants had to be on a concurrent treatment with at least one of the following (oral corticosteroids or immunosuppressants or both as defined below):

    • Stable oral corticosteroid dose (prednisone ≥ 20 mg/day or equivalent) for at least 14 days prior to baseline, or
    • Stable oral corticosteroid dose (prednisone \< 20 mg/day) for at least 21 days prior to baseline, and/or
    • At least a consecutive 12 weeks (84 days) course of AZA or 6-MP prior to baseline.

Exclusion criteria

Exclusion Criteria:

  1. Participants who had a history of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for UC or planned bowel surgery.
  2. Participants received previous treatment with adalimumab or previous participation in an adalimumab clinical study.
  3. Participants who had previously used infliximab or any anti- tumor necrosis factor (TNF) agent within 56 days of baseline (week 0).
  4. Participants who had previously used infliximab or any anti-TNF agent and had not clinically responded at any time ("primary non-responder") unless they experienced a treatment limiting reaction.
  5. Participants who had received cyclosporine, tacrolimus, or mycophenolate mofetil within 30 days of baseline (week 0).
  6. Participants who had received intravenous (IV) within 14 days of Screening or during the screening period.
  7. Participants who had a current diagnosis of fulminant colitis and/or toxic megacolon.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
463 participants (actual)

Study arms

  • Experimental
    Participants Receiving Adalimumab

    Adults with active UC who had failed conventional therapy received Adalimumab 160 mg at Baseline Visit, 80 mg at Week 2 Visit, and 40 mg every other week (EOW) starting at Week 4. Non-responders to adalimumab were to be discontinued from treatment at Week 8. After Week 8, dose escalation to 40 mg weekly was allowed for flare or non-response.

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Adalimumab pre-filled syringe, administered by subcutaneous injection

    Also known as: ABT-D2E7, Humira®

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score

    The SIBDQ is a disease-specific health-related quality of life (HRQOL) questionnaire, able to detect and define meaningful clinical changes in inflammatory bowel disease (IBD) participants by measuring physical, social and emotional status. The SIBDQ consists of 10 questions; each question is scored on a scale from 1 (poor QOL) to 7 (optimum QOL). A higher score indicates a better health-related quality of life. Total scores range from 10 (poor QoL) to 70 (good QoL).

    Time frame: Week 0 (baseline) and Week 26

  2. Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in Costs of UC-related Medical Care Excluding Adalimumab Costs

    Medical care costs included, but were not limited to: surgical procedures, hospitalizations, bed days in hospital, unscheduled physician consultations, emergency room visits, unscheduled examination appointments, radiology appointments, endoscopy appointments and medications.

    Time frame: 6 months prior to treatment start (Week 0 [baseline]) and 6 months after treatment start (total 12 months)

Secondary outcomes

  1. Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in Total All-cause Direct Health Care Costs (Excluding Adalimumab Costs)

    Medical care costs included, but were not limited to: surgical procedures, hospitalizations, bed days in hospital, unscheduled physician consultations, emergency room visits, unscheduled examination appointments, radiology appointments, endoscopy appointments and medications.

    Time frame: 6 months prior to treatment start (Week 0 [baseline]) and 6 months after treatment start (total 12 months)

  2. Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related Direct and Indirect Health Care Costs

    UC-related direct and indirect health care costs included, but were not limited to: surgical procedures, hospitalizations, bed days in hospital, unscheduled physician consultations, emergency room visits, unscheduled examination appointments, radiology appointments, endoscopy appointments, medications and indirect costs based on WPAI.

    Time frame: 6 months prior to treatment start (Week 0 [baseline]) and 6 months after treatment start (total 12 months)

  3. Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related and All-cause Hospitalization

    Hospitalization was defined as number of bed days in hospital as determined from the health care utilization information.

    Time frame: 6 months prior to treatment start (Week 0 [baseline]) and 6 months after treatment start (total 12 months)

  4. Mean Change From Baseline in Participant's Satisfaction Using Treatment Satisfaction Questionnaire for Medication (TSQM)

    TSQM is a questionnaire to be completed by the participants to determine their satisfaction of the medications for ulcerative colitis including the study drug. The TSQM is a 14-item subject-rated scale that evaluates the effectiveness, side effects, convenience, and global satisfaction of the medication over the past 2-3 weeks. Each of the 14 questions are scored from 1 (worst) to 7 points (best); and each of the domains are scored from 0 (less satisfaction) to 100 (better satisfaction). N = participants with evaluable baseline and post-baseline data.

    Time frame: Week 0 (baseline) and Week 26

  5. Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related Outpatient Utilization, Including Emergency Department Visits, Unscheduled Consultation, Exam Procedures

    UC-related outpatient utilization was determined from the health care utilization information. Outpatient utilization was the number of procedures/surgeries performed during outpatient visits. Participants without any outpatient utilization were excluded.

    Time frame: 6 months prior to treatment start (Week 0 [baseline]) and 6 months after treatment start (total 12 months)

  6. Percentage of Participants With Absence of Blood in Stool

    Participants with absence of blood in stool were reported.

    Time frame: Week 26

  7. Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score Over Time

    The SIBDQ is a disease-specific health-related quality of life (HRQoL) questionnaire, used to detect changes in inflammatory bowel disease (IBD) participants by measuring physical, social and emotional status. The SIBDQ consists of 10 questions, each question is scored on a scale from 1 (poor QoL) to 7 (good QoL). A higher score indicates a better health-related quality of life. Total scores range from 10 (poor QoL) to 70 (good QoL). N = participants with evaluable baseline and post-baseline data.

    Time frame: Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26

  8. Mean Change From Baseline in Physician's Global Assessment (PGA)

    The Physician's Global Assessment was used to measure the participant's disease activity. The physician considered the participant's reported information such as number of stools, rectal bleeding, abdominal discomfort, and functional assessment during the previous day prior to the visit, and other observations such as physical findings, and the participant's performance status at the time of the visit. Based on the above information the investigator made an overall assessment of participant's current severity of UC using the ordinal scale from 0 (normal) to 3 (severe disease).

    Time frame: Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26

  9. Mean Change From Baseline in Total Simple Clinical Colitis Activity Index (SCCAI)

    The SCCAI measures disease activity as assessed by the investigator and includes the following 6 items: bowel frequency (day), bowel frequency (night), urgency of defecation, blood in stool, general well-being and extra colonic features. The score ranges from 0 (best) to 19 points (worst).

    Time frame: Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26

  10. Mean Change From Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Total Score

    EQ-5D-5L Total Score provides a descriptive profile of health status. It comprises of 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) to describe the subject's current health state. Each dimension comprises 5 levels with corresponding numeric scores ranging from 1 (no problems) through 5 (extreme problems). A unique EQ-5D-5L health state was defined by combining the numeric level scores for each of the 5 dimensions and the total score ranges from -0.594 to 1, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement. N = participants with evaluable baseline and post-baseline data.

    Time frame: Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26

  11. Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Percentage of Work Time Missed

    WPAI-SHP is a questionnaire used to assess the effect of the participant's health problems on their ability to work and perform regular activities. A higher score indicates an increased impairment. A positive value of change indicates an increased impairment of work productivity and the limitation of activities of daily life, while a negative value indicates an improvement. The percentage of work time missed data was applicable to employed participants only. N = participants with evaluable baseline and post-baseline data.

    Time frame: Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26

  12. Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Percentage of Impairment While Working

    WPAI-SHP is a questionnaire used to assess the effect of the participant's health problems on their ability to work and perform regular activities. The scores on the WPAI questionnaire are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Change in WPAI-SHP was calculated by deducting the final score from the baseline score. A higher score indicates an increased impairment. A positive value of change indicates an increased impairment of work productivity and the limitation of activities of daily life, while a negative value indicates an improvement. The percentage of impairment while working data was applicable to employed participants only. N = participants with evaluable baseline and post-baseline data.

    Time frame: Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26

  13. Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Overall Work Impairment Percentage

    WPAI-SHP is a questionnaire used to assess the effect of the participant's health problems on their ability to work and perform regular activities. The scores on the WPAI questionnaire are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Change in WPAI-SHP was calculated by deducting the final score from the baseline score. A higher score indicates an increased impairment. A positive value of change indicates an increased impairment of work productivity and the limitation of activities of daily life, while a negative value indicates an improvement. The overall work impairment data was applicable to employed participants only. N = participants with evaluable baseline and post-baseline data.

    Time frame: Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26

  14. Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Percentage of Activity Impairment

    WPAI-SHP is a questionnaire used to assess the effect of the participant's health problems on their ability to work and perform regular activities. The scores on the WPAI questionnaire are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Change in WPAI-SHP was calculated by deducting the final score from the baseline score. A higher score indicates an increased impairment. A positive value of change indicates an increased impairment of work productivity and the limitation of activities of daily life, while a negative value indicates an improvement. N = participants with evaluable baseline and post-baseline data.

    Time frame: Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26

07

Results

Posted Nov 1, 2016

Participant flow

Participant flow — Overall Study
MilestoneParticipants Receiving Adalimumab
Started463
Completed353
Not completed110
Withdrew: Adverse event26
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up2
Withdrew: Lack of efficacy59
Withdrew: Other13

Outcome measures

PrimaryMean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score

The SIBDQ is a disease-specific health-related quality of life (HRQOL) questionnaire, able to detect and define meaningful clinical changes in inflammatory bowel disease (IBD) participants by measuring physical, social and emotional status. The SIBDQ consists of 10 questions; each question is scored on a scale from 1 (poor QOL) to 7 (optimum QOL). A higher score indicates a better health-related quality of life. Total scores range from 10 (poor QoL) to 70 (good QoL).

Time frame:
Week 0 (baseline) and Week 26
Reported as:
Mean · units on a scale
Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score
units on a scaleParticipants Receiving Adalimumab
Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score17.4 ± 14.48
Statistical analysis
  • Participants Receiving Adalimumab · paired t-test, 2 sided · p = <0.001 · Mean difference (final values): 17.40 · 95% CI 16.08 to 18.73
PrimaryMean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in Costs of UC-related Medical Care Excluding Adalimumab Costs

Medical care costs included, but were not limited to: surgical procedures, hospitalizations, bed days in hospital, unscheduled physician consultations, emergency room visits, unscheduled examination appointments, radiology appointments, endoscopy appointments and medications.

Time frame:
6 months prior to treatment start (Week 0 [baseline]) and 6 months after treatment start (total 12 months)
Reported as:
Mean · Pound Sterling (GBP)
Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in Costs of UC-related Medical Care Excluding Adalimumab Costs
Pound Sterling (GBP)Participants Receiving Adalimumab
Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in Costs of UC-related Medical Care Excluding Adalimumab Costs-1383.8 ± 2213.06
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (net): -1383.81 · 95% CI -1586.36 to -1181.26
SecondaryMean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in Total All-cause Direct Health Care Costs (Excluding Adalimumab Costs)

Medical care costs included, but were not limited to: surgical procedures, hospitalizations, bed days in hospital, unscheduled physician consultations, emergency room visits, unscheduled examination appointments, radiology appointments, endoscopy appointments and medications.

Time frame:
6 months prior to treatment start (Week 0 [baseline]) and 6 months after treatment start (total 12 months)
Reported as:
Mean · Pound Sterling (GBP)
Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in Total All-cause Direct Health Care Costs (Excluding Adalimumab Costs)
Pound Sterling (GBP)Participants Receiving Adalimumab
Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in Total All-cause Direct Health Care Costs (Excluding Adalimumab Costs)-1297.8 ± 2888.89
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (net): -1297.77 · 95% CI -1562.17 to -1033.36
SecondaryMean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related Direct and Indirect Health Care Costs

UC-related direct and indirect health care costs included, but were not limited to: surgical procedures, hospitalizations, bed days in hospital, unscheduled physician consultations, emergency room visits, unscheduled examination appointments, radiology appointments, endoscopy appointments, medications and indirect costs based on WPAI.

Time frame:
6 months prior to treatment start (Week 0 [baseline]) and 6 months after treatment start (total 12 months)
Reported as:
Mean · Pound Sterling (GBP)
Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related Direct and Indirect Health Care Costs
Pound Sterling (GBP)Participants Receiving Adalimumab
Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related Direct and Indirect Health Care Costs-4308.3 ± 7394.75
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (net): -4308.32 · 95% CI -4985.13 to -3631.51
SecondaryMean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related and All-cause Hospitalization

Hospitalization was defined as number of bed days in hospital as determined from the health care utilization information.

Time frame:
6 months prior to treatment start (Week 0 [baseline]) and 6 months after treatment start (total 12 months)
Reported as:
Mean · Days
Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related and All-cause Hospitalization
DaysParticipants Receiving Adalimumab
Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related and All-cause Hospitalization-7.3 ± 16.06
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (net): -7.3 · 95% CI -9.83 to -4.78
SecondaryMean Change From Baseline in Participant's Satisfaction Using Treatment Satisfaction Questionnaire for Medication (TSQM)

TSQM is a questionnaire to be completed by the participants to determine their satisfaction of the medications for ulcerative colitis including the study drug. The TSQM is a 14-item subject-rated scale that evaluates the effectiveness, side effects, convenience, and global satisfaction of the medication over the past 2-3 weeks. Each of the 14 questions are scored from 1 (worst) to 7 points (best); and each of the domains are scored from 0 (less satisfaction) to 100 (better satisfaction). N = participants with evaluable baseline and post-baseline data.

Time frame:
Week 0 (baseline) and Week 26
Reported as:
Mean · units on a scale
Mean Change From Baseline in Participant's Satisfaction Using Treatment Satisfaction Questionnaire for Medication (TSQM)
units on a scaleParticipants Receiving Adalimumab
Effectiveness (N=452)24.4 ± 31.09
Side Effects (N=449)18.9 ± 38.06
Convenience (N=451)6.2 ± 24.87
Global Satisfaction (N=449)22.6 ± 32.84
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): 24.37 · 95% CI 21.50 to 27.25
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): 18.95 · 95% CI 15.42 to 22.48
  • Participants Receiving Adalimumab · Paired t-test, 2 sided) · p = <0.001 · Mean difference (final values): 6.20 · 95% CI 3.89 to 8.50
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): 22.60 · 95% CI 19.55 to 25.64
SecondaryMean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related Outpatient Utilization, Including Emergency Department Visits, Unscheduled Consultation, Exam Procedures

UC-related outpatient utilization was determined from the health care utilization information. Outpatient utilization was the number of procedures/surgeries performed during outpatient visits. Participants without any outpatient utilization were excluded.

Time frame:
6 months prior to treatment start (Week 0 [baseline]) and 6 months after treatment start (total 12 months)
Reported as:
Mean · Procedures/ Surgeries
Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related Outpatient Utilization, Including Emergency Department Visits, Unscheduled Consultation, Exam Procedures
Procedures/ SurgeriesParticipants Receiving Adalimumab
Overall-4.8 ± 6.25
During emergency department visits0.0 ± 1.09
During primary care doctor visits-0.9 ± 2.82
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (net): -4.85 · 95% CI -5.42 to -4.27
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = 0.830 · Mean difference (net): -0.01 · 95% CI -0.11 to 0.09
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (net): -0.92 · 95% CI -1.18 to -0.66
SecondaryPercentage of Participants With Absence of Blood in Stool

Participants with absence of blood in stool were reported.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of Blood in Stool
percentage of participantsParticipants Receiving Adalimumab
Percentage of Participants With Absence of Blood in Stool56.6
Statistical analysis
  • Participants Receiving Adalimumab · McNemar · p = <0.001
SecondaryMean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score Over Time

The SIBDQ is a disease-specific health-related quality of life (HRQoL) questionnaire, used to detect changes in inflammatory bowel disease (IBD) participants by measuring physical, social and emotional status. The SIBDQ consists of 10 questions, each question is scored on a scale from 1 (poor QoL) to 7 (good QoL). A higher score indicates a better health-related quality of life. Total scores range from 10 (poor QoL) to 70 (good QoL). N = participants with evaluable baseline and post-baseline data.

Time frame:
Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26
Reported as:
Mean · units on a scale
Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score Over Time
units on a scaleParticipants Receiving Adalimumab
Week 2 (N=457)11.1 ± 9.81
Week 8 (N=459)15.4 ± 12.83
Week 18 (N=459)14.8 ± 13.06
Week 26 (N=460)17.4 ± 14.48
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): 11.11 · 95% CI 10.21 to 12.02
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): 15.38 · 95% CI 14.20 to 16.56
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): 14.77 · 95% CI 13.57 to 15.96
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): 17.40 · 95% CI 16.08 to 18.73
SecondaryMean Change From Baseline in Physician's Global Assessment (PGA)

The Physician's Global Assessment was used to measure the participant's disease activity. The physician considered the participant's reported information such as number of stools, rectal bleeding, abdominal discomfort, and functional assessment during the previous day prior to the visit, and other observations such as physical findings, and the participant's performance status at the time of the visit. Based on the above information the investigator made an overall assessment of participant's current severity of UC using the ordinal scale from 0 (normal) to 3 (severe disease).

Time frame:
Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26
Reported as:
Mean · units on a scale
Mean Change From Baseline in Physician's Global Assessment (PGA)
units on a scaleParticipants Receiving Adalimumab
Week 2-0.6 ± 0.69
Week 8-1.1 ± 0.85
Week 18-0.9 ± 0.95
Week 26-1.1 ± 0.97
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -0.63 · 95% CI -0.69 to -0.57
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -1.08 · 95% CI -1.16 to -1.00
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -0.86 · 95% CI -0.95 to -0.77
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -1.15 · 95% CI -1.23 to -1.06
SecondaryMean Change From Baseline in Total Simple Clinical Colitis Activity Index (SCCAI)

The SCCAI measures disease activity as assessed by the investigator and includes the following 6 items: bowel frequency (day), bowel frequency (night), urgency of defecation, blood in stool, general well-being and extra colonic features. The score ranges from 0 (best) to 19 points (worst).

Time frame:
Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26
Reported as:
Mean · units on a scale
Mean Change From Baseline in Total Simple Clinical Colitis Activity Index (SCCAI)
units on a scaleParticipants Receiving Adalimumab
Week 2-3.2 ± 2.55
Week 8-4.1 ± 3.33
Week 18-3.0 ± 3.79
Week 26-4.1 ± 3.88
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -3.22 · 95% CI -3.46 to -2.99
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -4.06 · 95% CI -4.37 to -3.76
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -3.01 · 95% CI -3.36 to -2.66
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -4.07 · 95% CI -4.43 to -3.72
SecondaryMean Change From Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Total Score

EQ-5D-5L Total Score provides a descriptive profile of health status. It comprises of 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) to describe the subject's current health state. Each dimension comprises 5 levels with corresponding numeric scores ranging from 1 (no problems) through 5 (extreme problems). A unique EQ-5D-5L health state was defined by combining the numeric level scores for each of the 5 dimensions and the total score ranges from -0.594 to 1, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement. N = participants with evaluable baseline and post-baseline data.

Time frame:
Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26
Reported as:
Mean · units on a scale
Mean Change From Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Total Score
units on a scaleParticipants Receiving Adalimumab
Week 2 (N=452)0.1 ± 0.18
Week 8 (N=454)0.1 ± 0.21
Week 18 (N=454)0.1 ± 0.22
Week 26 (N=454)0.1 ± 0.23
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): 0.10 · 95% CI 0.08 to 0.11
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): 0.13 · 95% CI 0.11 to 0.15
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): 0.12 · 95% CI 0.10 to 0.14
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): 0.14 · 95% CI 0.12 to 0.17
SecondaryMean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Percentage of Work Time Missed

WPAI-SHP is a questionnaire used to assess the effect of the participant's health problems on their ability to work and perform regular activities. A higher score indicates an increased impairment. A positive value of change indicates an increased impairment of work productivity and the limitation of activities of daily life, while a negative value indicates an improvement. The percentage of work time missed data was applicable to employed participants only. N = participants with evaluable baseline and post-baseline data.

Time frame:
Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26
Reported as:
Mean · percentage of work time missed
Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Percentage of Work Time Missed
percentage of work time missedParticipants Receiving Adalimumab
Week 2 (N=214)-8.6 ± 25.55
Week 8 (N=227)-12.2 ± 30.97
Week 18 (N=225)-11.6 ± 32.04
Week 26 (N=223)-11.4 ± 30.85
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -8.62 · 95% CI -12.07 to -5.18
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -12.22 · 95% CI -16.27 to -8.16
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -11.61 · 95% CI -15.82 to -7.40
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -11.43 · 95% CI -15.50 to -7.35
SecondaryMean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Percentage of Impairment While Working

WPAI-SHP is a questionnaire used to assess the effect of the participant's health problems on their ability to work and perform regular activities. The scores on the WPAI questionnaire are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Change in WPAI-SHP was calculated by deducting the final score from the baseline score. A higher score indicates an increased impairment. A positive value of change indicates an increased impairment of work productivity and the limitation of activities of daily life, while a negative value indicates an improvement. The percentage of impairment while working data was applicable to employed participants only. N = participants with evaluable baseline and post-baseline data.

Time frame:
Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26
Reported as:
Mean · percentage of impairment while working
Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Percentage of Impairment While Working
percentage of impairment while workingParticipants Receiving Adalimumab
Week 2 (N=221)-16.6 ± 25.94
Week 8 (N=234)-22.9 ± 30.91
Week 18 (N=232)-21.7 ± 30.98
Week 26 (N=229)-24.5 ± 29.78
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -16.56 · 95% CI -20.00 to -13.12
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -22.95 · 95% CI -26.93 to -18.97
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -21.68 · 95% CI -25.69 to -17.67
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -24.45 · 95% CI -28.33 to -20.58
SecondaryMean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Overall Work Impairment Percentage

WPAI-SHP is a questionnaire used to assess the effect of the participant's health problems on their ability to work and perform regular activities. The scores on the WPAI questionnaire are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Change in WPAI-SHP was calculated by deducting the final score from the baseline score. A higher score indicates an increased impairment. A positive value of change indicates an increased impairment of work productivity and the limitation of activities of daily life, while a negative value indicates an improvement. The overall work impairment data was applicable to employed participants only. N = participants with evaluable baseline and post-baseline data.

Time frame:
Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26
Reported as:
Mean · percentage of overall work impairment
Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Overall Work Impairment Percentage
percentage of overall work impairmentParticipants Receiving Adalimumab
Week 2 (N= 211)-18.3 ± 27.72
Week 8 (N= 225)-26.5 ± 34.56
Week 18 (N= 223)-25.3 ± 35.10
Week 26 (N= 221)-29.2 ± 32.32
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -18.34 · 95% CI -22.10 to -14.57
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -26.54 · 95% CI -31.08 to -22.00
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -25.33 · 95% CI -29.97 to -20.70
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -29.22 · 95% CI -33.50 to -24.93
SecondaryMean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Percentage of Activity Impairment

WPAI-SHP is a questionnaire used to assess the effect of the participant's health problems on their ability to work and perform regular activities. The scores on the WPAI questionnaire are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Change in WPAI-SHP was calculated by deducting the final score from the baseline score. A higher score indicates an increased impairment. A positive value of change indicates an increased impairment of work productivity and the limitation of activities of daily life, while a negative value indicates an improvement. N = participants with evaluable baseline and post-baseline data.

Time frame:
Week 0 (baseline), Week 2, Week 8, Week 18, and Week 26
Reported as:
Mean · percentage of activity impairment
Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Percentage of Activity Impairment
percentage of activity impairmentParticipants Receiving Adalimumab
Week 2 (N=435)-18.2 ± 24.55
Week 8 (N=446)-25.4 ± 30.84
Week 18 (N=446)-24.4 ± 31.35
Week 26 (N-446)-27.2 ± 32.83
Statistical analysis
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -18.16 · 95% CI -20.47 to -15.85
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -25.43 · 95% CI -28.30 to -22.56
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -24.42 · 95% CI -27.33 to -21.50
  • Participants Receiving Adalimumab · Paired t-test, 2 sided · p = <0.001 · Mean difference (final values): -27.22 · 95% CI -30.28 to -24.16

Adverse events

Collected over Adverse Events were collected from the time of study drug administration to 70 days after last dose of study drug (up to 36 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PARTICIPANTS RECEIVING ADALIMUMAB—67/463 (14.5%)178/463 (38.4%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventPARTICIPANTS RECEIVING ADALIMUMAB
COLITIS ULCERATIVEGastrointestinal disorders41/463
ANAEMIABlood and lymphatic system disorders2/463
ABORTION INDUCEDSurgical and medical procedures2/463
PANCYTOPENIABlood and lymphatic system disorders1/463
THROMBOCYTOPENIABlood and lymphatic system disorders1/463
SILENT MYOCARDIAL INFARCTIONCardiac disorders1/463
HYPERTHYROIDISMEndocrine disorders1/463
ABDOMINAL PAIN LOWERGastrointestinal disorders1/463
DIARRHOEAGastrointestinal disorders1/463
GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders1/463
Most frequent other events
Most frequent other events
EventPARTICIPANTS RECEIVING ADALIMUMAB
COLITIS ULCERATIVEGastrointestinal disorders61/463
HEADACHENervous system disorders60/463
NASOPHARYNGITISInfections and infestations37/463
ARTHRALGIAMusculoskeletal and connective tissue disorders33/463
NAUSEAGastrointestinal disorders29/463
COUGHRespiratory, thoracic and mediastinal disorders27/463
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders25/463

Baseline characteristics

Intention to Treat (ITT) population: all participants who had received at least one dose of study drug and had data for at least one post-baseline assessment of any effectiveness measurement \[up to and including Week 26\] while receiving treatment with adalimumab.

Age, Continuous
Age, Continuous(years)Participants Receiving Adalimumab
Mean41.8 ± 13.75
Sex: Female, Male
Sex: Female, Male(Participants)Participants Receiving Adalimumab
Female206
Male255
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, Robinson AM, Petersson J, Pappalardo BL, Bereswill M, Chen N, Wang S, Skup M, Thakkar RB, Chao J. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis. 2017 Oct 27;11(11):1317-1325. doi: 10.1093/ecco-jcc/jjx093. PubMed 28981846 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2012
First posted
Mar 12, 2012
Start
May 2012
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Nov 1, 2016
Last update
Jul 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01550965
Responsible party
Sponsor
First posted
Mar 12, 2012
Start date
May 2012
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Nov 1, 2016
Last update
Jul 2, 2018

Study contacts

John Medich
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion